H.C. Wainwright Reiterates 'Buy' Rating on Day One Biopharmaceuticals, Inc. (DAWN)

With significant hedge fund interest and a share price under $10, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds.

On August 6, 2025, H.C. Wainwright reiterated its ‘Buy’ rating on Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) with a $25 price target. Meanwhile, on the same day, JPMorgan also maintained its ‘Buy’ rating, citing the strong growth trajectory of Ojemda for recurrent or refractory pediatric low-grade glioma (r/r pLGG). The U.S. peak sales for the medicine are projected to surpass $500 million.

Furthermore, the investment firm highlighted the company’s guidance for 2025 of $140-150 million in sales, underpinned by robust patient starts, persistence rates, and stable gross-to-net (GTN) ratios, which are expected to remain steady despite the recent price increase. Meanwhile, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)’s sequential quarterly growth in patient volume continues. Lastly, the analyst cited the awaited update from the FIREFLY-1 Cohort 1 study on Ojemda’s long-term safety and efficacy. Positive results from the study could further strengthen confidence in the drug’s market potential.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) develops targeted therapies for childhood and adult cancers. It is included in our list of the Best Single Digit Stocks.

While we acknowledge the potential of DAWN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.